Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 μg | $247 | In Stock | |
50 μg | $384 | 7-10 days | |
100 μg | $597 | 7-10 days | |
200 μg | $968 | 7-10 days |
Biological Information | Tested by Flow cytometric analysis of anti-BCMA CAR expression. |
Description | BCMA/TNFRSF17 Protein, Human (His & hFc), PE conjugated is expressed in HEK293 mammalian cells with His and Fc tag. The accession number is NP_001183.2. |
Species | Human |
Expression System | HEK293 Cells |
Tag | His, Fc |
Accession Number | NP_001183.2 |
Synonyms | BCMA,TNFRSF13A,tumor necrosis factor receptor superfamily member 17,BCM,CD269 |
Construction | Recombinant Human BCMA/TNFRSF17 (NP_001183.2, extracellular domain, Met 1-Ala 54) are conjugated with PE under optimum conditions, the unreacted PE was removed. |
Formulation | Aqueous solution containing 0.5% BSA and 0.03% Proclin 300 |
Stability & Storage | This reagent is stable for 6 months when stored at 2°C-8°C. Protected from prolonged exposure to light. Do not freeze! |
Shipping | Shipping with blue ice. |
Research Background | Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.